Brief: Scynexis Presents Positive Interim Data Of Ibrexafungerp For Refractory Candida Infections
08/09/2022 13:31
Sept 8 (Reuters) - SCYNEXIS Inc SCYX.O :
* SCYNEXIS PRESENTS POSITIVE INTERIM DATA OF IBREXAFUNGERP
FOR
REFRACTORY CANDIDA INFECTIONS FROM ONGOING PHASE 3 FURI STUDY
DURING THE MYCOSES STUDY GROUP EDUCATION AND RESEARCH CONSORTIUM
(MSGERC) BIENNIAL MEETING
* SCYNEXIS INC - APPROXIMATELY 83% OF FURI PATIENTS WITH
REFRACTORY CANDIDA INFECTIONS HAD POSITIVE CLINICAL OUTCOME
Source text for Eikon: ID:nGNX5Cs2FF
Further company coverage: SCYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview